Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.26 USD
Change Today -0.28 / -3.28%
Volume 1.0M
AGEN On Other Exchanges
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by AGENUS INC (AGEN) in the last 6 months

Announced 07/20/15
44.00M for DIATHEVA s.r.l., Rights of Carcinoembryonic Antigen Cell Adhesion Molecule 1

Agenus Inc. (NasdaqCM:AGEN) acquired rights of Carcinoembryonic Antigen Cell Adhesion Molecule 1 from DIATHEVA s.r.l. for $44 million on July 20, 2015. Under the terms of the agreement, the consideration involves certain upfront, early development, clinical trial and regulatory milestone payments for the successful development of CEACAM1 antibodies totaling as much as $44 million. Diatheva is also eligible to receive additional sales milestones and royalties. Brad Miles ...
Read More

AGEN's price was unchanged after the transaction was announced on 07/20/15.
Investor / Buyer
Agenus Inc.
Creditor / Lender
Announced 04/8/15
10.00M for Celexion, LLC

Agenus Inc. (NasdaqCM:AGEN) acquired assets of Celexion, LLC from Flagship Ventures Fund 2007 LP fund of Flagship Ventures, Brian M. Baynes and Alexandria Equities, LLC for $10 million on April 7, 2015. Included in the asset acquisition is the SECANT(R) yeast display platform for the generation of novel monoclonal antibodies, key antibody assets, Celexion's novel approaches to generate antibodies against membrane bound protein targets such as GPCRs and ion channels. ...
Read More

AGEN's price was unchanged after the transaction was announced on 04/8/15.
Investor / Buyer
Agenus Inc.
Creditor / Lender
Alexandria Equities, LLC
Flagship Ventures
Flagship Ventures Fund 2007, L.P.
Legal Advisor
Goodwin Procter LLP

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGEN:US $8.26 USD -0.28

AGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.3x
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at